Efficacy observation of irbesartan combined amlodipine in treatment of hypertension and diabetic nephropathy / 中国生化药物杂志

ABSTRACT

Objective To explore the therapeutic efficacy of irbesartan combined amlodipine for the treatment of hypertension and diabetic nephropathy.Methods 120 patients with diabetic nephropathy and hypertension received from March 2011 to March 2014 were randomly divided into three groups according to its administration circumstances ( irbesartan group and amlodipine group, irbesartan and amlodipine groups) , with 40 patients in each group.Blood pressure, 24h urine albumin, 24h urinary protein excretion and urine β2-microglobulin and other indicators of the three groups of patients were observed and compared after 10 weeks of treatment.Results After treatment, the total efficiency of A, B two groups was no significant difference.The total effective rate of group C (92.5%) was significantly higher than that in A group (χ2 =6.65, P<0.05), the total effective rate of group C was significantly higher than that of group B (χ2 =7.81, P<0.05).The blood pressure in patients of three groups were all dropped to normal after treatment, but the one in combination group was significantly lower than the irbesartan group and amlodipine group, the difference was statistically significant (P<0.05).The urine tests related indicators of patients in the three groups were also significantly reduced after treatment , but 24 h urine albumin, 24 h urinary protein excretion and urine β2-microglobulin in combination group were significantly lower than the irbesartan group and amlodipine group, the difference was statistically significant (P<0.05).Three groups were no obvious adverse reactions. Conclusion Irbesartan combined amlodipine for the treatment of hypertension and diabetic nephropathy has significant efficacy compared to single drug.